Description: Next Science Limited, a medical technology company, develops and commercializes non-toxic technology products with efficacy in eradicating biofilm based and free-floating bacteria. The company develops its products using its Xbio Technology platform. It offers SurgX, an innovative surgical gel designed to reduce superficial surgical site infections and protect wound tissue to facilitate natural healing; and Bactisure, a surgical lavage that is used to remove debris, including microorganisms from wounds. The company also provides TorrentX, an antimicrobial wound wash; and BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment. In addition, it is developing acne gel; middle ear wash for use in patients with chronic ear infections; minimally invasive surgical lavage to replace a saline wound lavage; nasal packing stent for use in recovery from nasal surgery; adhesion barrier that is implanted in surgery field to prevent internal adhesion; and soft coating for implants. Further, the company develops tropical treatments for school sores, infected atopic dermatitis, and fungal nails; tropical preventative treatment for keloid scarring; and products for bacterial vaginosis, as well as over the counter products, such as mouthwash. Next Science Limited was founded in 2012 and is headquartered in Sydney, Australia.
Home Page: www.nextscience.com
The Zenith Building, Tower A
Chatswood,
NSW
2067
Australia
Phone:
61 2 8607 5126
Officers
Name | Title |
---|---|
Ms. Judith Mitchell M.B.A. | MD, CEO & Exec. Director |
Dr. Matthew Franco Myntti | Founder & CTO |
Ms. Jacqueline Butler CA (ICAEW) | Chief Financial Officer |
Mr. Jon Swanson | Chief Operating Officer |
Mr. Michael Morello | VP of Sales |
Ms. Gillian Maria Nairn AGIA, B.A., BA, L.L.B., L.L.M., LLB, LLM, MAICD | Company Sec. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
Forward PE: | 9.1659 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 7.2159 |
Price-to-Sales TTM: | 9.2052 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 0 |